Read, Watch or Listen

Eli Lilly announced positive late-stage trial results for its oral obesity drug, orforglipron, showing nearly 12% weight loss in patients at the highest dose. While slightly lower than expectations and comparable to Novo Nordisk's Wegovy, doctors praised its potential to reach patients averse to injections. Despite a stock dip, Eli Lilly plans to submit the data to regulators this year for a 2026 launch. The pill could significantly expand access to obesity treatments, addressing current supply constraints and potentially lower costs compared to injectable options.

Prepared by Olivia Bennett and reviewed by editorial team.